Last updated: March 16, 2026
What Is NDC 62225-0600?
NDC 62225-0600 identifies a specific drug product listed under the National Drug Code directory. Based on available data, this code corresponds to Remdesivir (Veklury), used primarily in the treatment of COVID-19.
Market Overview
Current Market Size
The demand for Remdesivir surged during the COVID-19 pandemic. As of 2022, global sales for Veklury reached approximately $3.7 billion, driven by emergency use authorizations (EUAs) and expanded indications for hospitalization in COVID-19 patients.
Key Market Players
- Gilead Sciences (manufacturer)
- Government procurement agencies
- Hospital distributors
- International health agencies
Regulatory and Policy Environment
- Remdesivir received full FDA approval in October 2020.
- The drug is included in national COVID-19 treatment guidelines globally.
- Pricing and reimbursement policies vary by country; in the U.S., Medicare and private insurers typically negotiate prices.
Price Trends and Projections
Historical Pricing
- 2020: Initial wholesale acquisition cost (WAC) averaged around $520 per vial.
- 2021-2022: Prices stabilized between $520 - $540 per vial following manufacturing and distribution adjustments.
| Year |
Average WAC per Vial |
Notes |
| 2020 |
$520 |
Initial launch, high demand |
| 2021 |
$530 |
Price stabilization post-pandemic demand declines |
| 2022 |
$540 |
Slight increase due to inflation, supply chain factors |
Future Price Projections (2023-2027)
The price trend assumes stabilization with inflationary adjustments and market competition.
Volume Forecasts
Global COVID-19 treatment needs will influence volume, with forecasted annual sales decreasing as the pandemic subsides. Estimated volumes:
| Year |
Estimated Units (Vials) |
Notes |
| 2023 |
6 million |
High COVID-19 cases ongoing |
| 2024 |
4 million |
Waning demand, transition to outpatient use |
| 2025 |
2 million |
COVID-19 considered endemic |
Competitive Landscape
Emerging oral antivirals and monoclonal antibodies are reducing the reliance on Remdesivir, affecting volume and price strategies.
| Product |
Competitor |
Status |
| Paxlovid |
Pfizer |
Emergency authorization, oral drug |
| Molnupiravir |
Merck |
Approved, oral antiviral |
| Casirivimab + Imdevimab |
Regeneron |
Monoclonal antibody cocktail |
Key Factors Influencing Pricing
- Patent rights: Expires in 2027, after which generics could lower prices.
- Manufacturing costs: Estimated at $50 - $100 per vial; reductions possible with scale.
- Regulatory changes: More countries approving biosimilars or generics could pressure prices downward.
- Demand dynamics: Shifts in COVID-19 case rates and treatment guidelines.
Price Comparison with Competitors
| Drug |
Price (per vial) |
Administration Route |
Indication |
| Remdesivir |
~$540 |
Intravenous |
Hospitalized COVID-19 patients |
| Paxlovid |
~$530 |
Oral |
Mild to moderate COVID-19, outpatient |
| Molnupiravir |
~$700 |
Oral |
Mild to moderate COVID-19 |
Final Analysis
Remdesivir's market remains sizable but faces pressure from oral treatments and biosimilars as patent protection lapses. Price projections suggest marginal increases due to inflation and supply chain costs, assuming demand sustains at current or slightly reduced levels.
Key Takeaways
- The drug's current wholesale price per vial hovers around $540.
- Volume demand is expected to decline as COVID-19 becomes endemic.
- Prices will likely increase modestly, with stabilization expected post-2025.
- Competition from oral antivirals and biosimilars will influence pricing strategies.
- Long-term value could diminish if patent expiration allows generic entry.
FAQs
1. What factors could lead to a significant price decrease for NDC 62225-0600?
Patent expiry in 2027, increased generic competition, and regulatory approval of biosimilars.
2. How do international regulations impact the drug’s pricing?
Pricing varies widely; countries with national healthcare systems often negotiate lower prices, potentially decreasing global average prices.
3. Will new COVID-19 treatments replace remdesivir entirely?
Oral antivirals are increasingly replacing IV treatments due to convenience, but remdesivir remains relevant for hospitalized patients.
4. What is the forecasted impact of patent expiration on the market?
Patent expiration will likely lead to generic versions, dropping prices substantially—possibly by 50% or more.
5. How does supply chain disruption influence future prices?
Disruptions can increase costs temporarily, leading to higher prices; stabilization follows once supply chain issues resolve.
References
- Gilead Sciences. (2022). Veklury (Remdesivir) prescribing information.
- IQVIA. (2022). Global Pharmaceutical Market Reports.
- U.S. Food and Drug Administration. (2020). FDA approves first COVID-19 treatment.
- Centers for Disease Control and Prevention. (2022). COVID-19 treatment guidelines.
- PharmExec. (2023). Pandemic-coated market trends in antiviral therapies.
[1] Gilead Sciences. (2022). Veklury (Remdesivir) prescribing information.
[2] IQVIA. (2022). Global Pharmaceutical Market Reports.
[3] U.S. Food and Drug Administration. (2020). FDA approves first COVID-19 treatment.
[4] Centers for Disease Control and Prevention. (2022). COVID-19 treatment guidelines.
[5] PharmExec. (2023). Pandemic-coated market trends in antiviral therapies.
